A Competitive Analysis of the Global Acute Coronary Syndrome
(ACS) Therapeutics Market is part of theLife Sciences Growth Partnership Service program.
It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome
and special features on late-stage and discontinued projects.
Eligible patients presenting with acute coronary syndrome
(specifically, a heart attack) will be randomised to receive three months of twice daily oral treatment with either 7.
We would like to thank the authors of the letter for their interest and criticism about our study published in The Anatolian Journal of Cardiology (1) on predictive value of mean platelet volume (MPV) in young patients with non-ST-segment elevation acute coronary syndromes
The new programme should lead to a reduction in the length of stay in hospital for patients with acute coronary syndrome
as well as a reduction in the number of patients readmitted to hospital.
Future studies should focus on identifying the reasons that women appear less likely than men to accept physician-recommended tests and treatments for acute coronary syndrome
The Phase II Japanese trial in acute coronary syndrome
Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes
The research will be aimed at identifying cardiovascular risk factors that can be used alone or in combination with other clinical measures to improve stratification and management of acute coronary syndrome
The Acute Coronary Syndrome
- US Drug Forecast and Market Analysis to 2023 report estimates that the total market size for the 7MM in 2013 was $12.
Based on co-development of the agent outside of Japan by Daiichi Sankyo and Eli Lilly and Company, the European Commission and the US FDA granted marketing authorization for EfientA/EffientA for the prevention of atherothrombotic events in patients with acute coronary syndrome
(ACS) undergoing PCI, in combination with aspirin, in 2009.
In another study, khat users presenting with acute coronary syndrome
had worse in-hospital and one-year outcome, as compared with non-users (3).